Smart dosing of rituximab may keep rare blood vessel disease at bay
NCT ID NCT01731561
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tested two ways of giving rituximab to people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. All 166 participants were in remission and received rituximab either on a fixed schedule or only when certain blood markers (ANCA or CD19 cells) reappeared. The goal was to see which approach better prevents relapses over 18 months of treatment plus 10 months of follow-up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab
- What this could lead to
- If successful, this could show that monitoring blood markers to guide rituximab dosing is as effective as fixed infusions, potentially reducing treatment burden.
- What could go wrong
- This is a completed phase 3 trial, but results may not apply to all patients. Rituximab carries risks like infusion reactions and increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin Hospital
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug shield kidneys from autoimmune attack?
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- Hydroxychloroquine trial for rare vasculitis halted early
- New hope for Wegener's patients: drug aims to stop flare-ups
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders